menu
    • menu
    [{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Masupirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Masupirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Masupirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Masupirdine","moa":"||Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Masupirdine","moa":"||Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Masupirdine

    Menu

    Masupirdine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Suven Life Sciences Breathes New Life Into Drug Discovery Plans

                            Details : SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2023

                            Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Masupirdine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

                            Details : Masupirdine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psychomotor Agitation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 31, 2022

                            Lead Product(s) : Masupirdine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Suven Life Sciences Announces Phase 3 Clinical Trial of SUVN-502 for Treatment of Agitation and Aggression in ...

                            Details : SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer’s disease without meeting primary end point.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2021

                            Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Masupirdine

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

                            Details : SUVN-502 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 21, 2018

                            Lead Product(s) : Masupirdine

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed

                            Suven Life Sciences Limited

                            India arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Masupirdine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

                            Details : SUVN-502 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2015

                            Lead Product(s) : Masupirdine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth